77901-50-9

Usage

Uses

Used in Pharmaceutical Synthesis:
[(2-chlorophenyl)amino](oxo)acetic acid is used as an intermediate in the synthesis of pharmaceuticals for its unique structural properties. The presence of the chlorophenyl group and the amino group allows for the creation of a wide range of therapeutic compounds with diverse biological activities.
Used in Agrochemical Synthesis:
In the agrochemical industry, [(2-chlorophenyl)amino](oxo)acetic acid is used as a building block for the development of new agrochemicals. Its chemical structure can be modified to create compounds with specific pesticidal, herbicidal, or fungicidal properties, contributing to the control of various agricultural pests and diseases.
Used in Organic Chemistry:
[(2-chlorophenyl)amino](oxo)acetic acid serves as a versatile starting material in organic chemistry for the synthesis of various organic compounds. Its functional groups can be further modified or reacted with other molecules to produce a wide array of products with different applications in the chemical industry.
Used in Medical Research:
[(2-chlorophenyl)amino](oxo)acetic acid is used as a research compound for investigating its potential biological activities, such as antifungal and antibacterial properties. These studies may lead to the development of new treatments for various infections and diseases.
Used in the Treatment of Schizophrenia and Neurological Disorders:
In the medical field, [(2-chlorophenyl)amino](oxo)acetic acid is being explored for its potential use in the treatment of schizophrenia and neurological disorders. Its unique chemical structure may offer new therapeutic avenues for managing these complex conditions.

InChI:InChI=1/C8H6ClNO3/c9-5-3-1-2-4-6(5)10-7(11)8(12)13/h1-4H,(H,10,11)(H,12,13)

Upstream product

• 50982-66-6 N-(2-chlorophenyl)-2-cyanoacetamide 
• 144-62-7 oxalic acid 
• 95-51-2 o-chloroaniline 
• 53117-16-1 ethyl N-(2-chlorophenyl)oxamate 
• 882494-57-7 methyl 2-((2-chlorophenyl)amino)-2-oxoacetate 

Downstream Products

• 1040762-99-9 C₂₁H₁₁BrCl₂F₃N₃O₃ 
• 868565-91-7 (S)-5-Bromo-3-{(S)-2-[(2-chloro-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-pentanoic acid tert-butyl ester 
• 868565-80-4 (S)-2-{(S)-2-[(2-Chloro-phenylaminooxalyl)-amino]-propionylamino}-succinic acid 4-tert-butyl ester 

Relevant academic research and scientific papers

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease

A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

Synthesis, crystal structure, and insecticidal activity of novel N-alkyloxyoxalyl derivatives of 2-arylpyrrole

Two series of novel N-alkyloxyoxalyl derivatives of 2-arylpyrrole were synthesized, and their structures were characterized by 1H NMR spectroscopy, elemental analysis, and single-crystal X-ray diffraction analysis. The insecticidal activities of the new compounds were evaluated. The results of bioassays indicated that some of these title compounds exhibited excellent insecticidal activities, and their insecticidal activities against oriental armyworm, mosquito, and spider mite are comparable to those of the commercialized Chlorfenapyr.

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.